Product Center
Breaking through Bottleneck Technology, Significant Progress has been Made in the Research and Development of New Adjuvants
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-08-26
- Views:
(Summary description)On August 25th, the R&D team of Yither Biotech (Shanghai) Co., Ltd., a wholly-owned subsidiary of Ab&B Bio-Tech Co., Ltd. (Ab&B Bio), made a breakthrough in the field of innovative adjuvant research and development. The research results were published online in the internationally renowned journal Journal of Drug Delivery Science and Technology under the title "Dual functional Emulsifier-Based Nanoemulsification Adjuvant Effectively Enhanced Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine in Mice".
Breaking through Bottleneck Technology, Significant Progress has been Made in the Research and Development of New Adjuvants
(Summary description)On August 25th, the R&D team of Yither Biotech (Shanghai) Co., Ltd., a wholly-owned subsidiary of Ab&B Bio-Tech Co., Ltd. (Ab&B Bio), made a breakthrough in the field of innovative adjuvant research and development. The research results were published online in the internationally renowned journal Journal of Drug Delivery Science and Technology under the title "Dual functional Emulsifier-Based Nanoemulsification Adjuvant Effectively Enhanced Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine in Mice".
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-08-26 18:05
- Views:
On August 25th, the R&D team of Yither Biotech (Shanghai) Co., Ltd., a wholly-owned subsidiary of Ab&B Bio-Tech Co., Ltd. (Ab&B Bio), made a breakthrough in the field of innovative adjuvant research and development. The research results were published online in the internationally renowned journal Journal of Drug Delivery Science and Technology under the title "Dual functional Emulsifier-Based Nanoemulsification Adjuvant Effectively Enhanced Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine in Mice".

Subunit vaccines, genetically engineered vaccines, etc. usually require the addition of adjuvants to enhance their immunogenicity and activate effective immune responses. However, the number of components in a vaccine is not necessarily better, and adjuvants that combine delivery and immune stimulation functions are the most ideal. Therefore, the company's R&D team targeted different types of immune responses, combined with the structural characteristics of immune stimulators, while ensuring safety, and took the lead in using emulsifiers with immune stimulatory functions to develop efficient preparation processes and unique nanoemulsion adjuvants. The results of animal experiments show that the use of this adjuvant, combined with our self-developed recombinant protein antigen, can effectively stimulate the body's humoral and cellular immune responses. Compared with MF59 and aluminum/CpG adjuvant systems, it exhibits significant advantages. Currently, the adjuvant can achieve GMP production, and the invention patent for "a nanoemulsion adjuvant (application number 2023103883104)" based on the adjuvant application has also entered the substantive examination stage.
Ab&B Bio actively expands into the field of innovative adjuvants, focusing on the research and development of "nano adjuvant formulations, new immunostimulants, and composite adjuvant systems". Based on antigen characteristics, it develops its exclusive adjuvants and production processes, aiming to efficiently enhance the body's immune response, reduce the risk of adverse reactions, and reduce the amount of antigen used. The company is independently developing multiple adjuvants and gradually applying them to innovative products such as pneumococcal polysaccharide conjugate vaccines, recombinant herpes zoster vaccines, and recombinant respiratory syncytial virus vaccines, providing an "acceleration" for the company's innovative vaccine production.
Relevant information
-
How to choose a reliable influenza vaccine during the flu season? An evidence-based guide for subunit vaccines for all age groups
Influenza (commonly referred to as the flu) is an acute respiratory infectious disease caused by the influenza virus. Unlike the common cold, influenza is highly contagious and is characterized primarily by systemic symptoms. Elderly individuals, children under the age of 5, patients with chronic diseases, pregnant women, and individuals with compromised immune systems are all considered high-risk populations for severe influenza [1]. A study based on national influenza surveillance and cause-of-death surveillance data revealed that, on average, there are 88,000 excess deaths related to influenza-associated respiratory diseases annually across China [2]. The total economic burden on outpatient patients with influenza ranges from RMB 801 to RMB 1,320, while the total economic burden on hospitalized influenza patients ranges from RMB 9,832 to RMB 23,833 [1]. In the face of the significant challenge posed by influenza, influenza vaccination is currently recognized worldwide as the most cost-effective and effective means of preventing influenza [1]. - The leap in influenza vaccine technology: from split-virus vaccines to whole-population subunit vaccines – what are the key advancements in the third-generation vaccines? 08-19
- Exclusive Release | The influenza subunit vaccine "HRK-X® 3" makes its nationwide debut, ushering in a new chapter of scientific protection for all populations! 08-15
- High-dose influenza vaccines now available across the entire population – marking a new phase in influenza prevention and control with subunit vaccines 08-15
- Deepening Strategic Synergy to Jointly Strengthen Public Health Defense: Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio for a visit and exchange session. 08-06
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us